Another study found that the combination of the BET inhibitor ABBV-075 and venetoclax showed a strong synergistic inhibitory effect on SCLC, and this effect was positively correlated with the expression of BCL2 [40]. This evidence concerns the gene BCL2 and small cell lung carcinoma.